🇺🇸 FDA

Company profile · Sponsor

Formycon

Formycon AG

EA41F04 · EMA pharma Planegg, DE
Pipeline
2
Drugs
0
Patents
0

Quick answer

Formycon (EA41F04) is a pharma company. headquartered in Planegg, DE. listed on EMA. NovaPharmaNews links 2 pipeline programs, 0 drugs, and 0 patents to this profile..

Company facts

Ticker EA41F04
Exchange EMA
Company type pharma
Headquarters Planegg, DE

Pipeline (2)

Search pipeline →

  1. KEYTRUDA 25 mg/mL concentrate for solution for infusion, FYB206, KEYTRUDA 25 mg/mL concentrate for solution for infusion, KEYTRUDA 25 mg/mL concentrate for solution for infusion, KEYTRUDA 25 mg/mL concentrate for solution for infusion

    Formycon

    NSCLC

    phase 3 small molecule active

    1 trial

  2. Assessment of Pharmacokinetic Similarity of FYB206 in Comparison with Keytruda in Resected Stage II or Stage III Melanoma Patients

    Formycon

    Melanoma: Adjuvant treatment of patients with Stage IIB, IIC, or III melanoma following complete resection

    phase 1 other active

    1 trial

Frequently asked questions

What is Formycon?

Formycon (EA41F04) is a pharma company. headquartered in Planegg, DE. listed on EMA. NovaPharmaNews links 2 pipeline programs, 0 drugs, and 0 patents to this profile..

What pipeline programs does Formycon sponsor?

We track 2 ClinicalTrials.gov-linked programs for Formycon, including KEYTRUDA 25 mg/mL concentrate for solution for infusion, FYB206, KEYTRUDA 25 mg/mL concentrate for solution for infusion, KEYTRUDA 25 mg/mL concentrate for solution for infusion, KEYTRUDA 25 mg/mL concentrate for solution for infusion and 1 more. Open each program for phase, modality, NCT IDs, and indication details.

Where does Formycon company data come from?

Profiles combine SEC EDGAR (CIK/ticker), ClinicalTrials.gov sponsor links, FDA drug records, and USPTO patent metadata. See our data sources page. This profile is for professional reference, not investment advice.